Biren Amin
Stock Analyst at Piper Sandler
(2.04)
# 1,580
Out of 4,667 analysts
46
Total ratings
36.59%
Success rate
-4.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMNM Immunome | Maintains: Overweight | $23 → $21 | $9.33 | +125.08% | 3 | Nov 14, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $11 → $9 | $2.05 | +339.02% | 2 | Nov 14, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $91 → $115 | $87.22 | +31.85% | 2 | Nov 8, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $40 → $32 | $27.49 | +16.41% | 2 | Nov 6, 2024 | |
| BBIO BridgeBio Pharma | Initiates: Overweight | $46 | $23.04 | +99.65% | 1 | Sep 4, 2024 | |
| CRGX CARGO Therapeutics | Maintains: Overweight | $37 → $34 | $15.82 | +114.92% | 2 | Aug 13, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $205 → $200 | $110.86 | +80.41% | 4 | Aug 8, 2024 | |
| AGEN Agenus | Downgrades: Hold | $7 → $3 | $2.67 | +12.36% | 1 | Jul 19, 2024 | |
| SLDB Solid Biosciences | Reiterates: Overweight | $20 | $4.96 | +303.23% | 1 | Jun 21, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $15 | $8.78 | +70.84% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $0.58 | +1,620.87% | 1 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $3.13 | +2,136.42% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.48 | +3,345.95% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $4.76 | +404.20% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $2.01 | +1,591.54% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $6.43 | +7,676.05% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $7.80 | +79.49% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $743.35 | -7.04% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $0.87 | +1,049.29% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $0.30 | - | 4 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $20.31 | +397.29% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $123.29 | -44.03% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $451.23 | -65.65% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $2.12 | +6,315.09% | 4 | Mar 6, 2017 |
Immunome
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $9.33
Upside: +125.08%
Allogene Therapeutics
Nov 14, 2024
Maintains: Overweight
Price Target: $11 → $9
Current: $2.05
Upside: +339.02%
Arcellx
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $87.22
Upside: +31.85%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $27.49
Upside: +16.41%
BridgeBio Pharma
Sep 4, 2024
Initiates: Overweight
Price Target: $46
Current: $23.04
Upside: +99.65%
CARGO Therapeutics
Aug 13, 2024
Maintains: Overweight
Price Target: $37 → $34
Current: $15.82
Upside: +114.92%
Sarepta Therapeutics
Aug 8, 2024
Maintains: Overweight
Price Target: $205 → $200
Current: $110.86
Upside: +80.41%
Agenus
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $2.67
Upside: +12.36%
Solid Biosciences
Jun 21, 2024
Reiterates: Overweight
Price Target: $20
Current: $4.96
Upside: +303.23%
Ocular Therapeutix
Jun 21, 2024
Maintains: Overweight
Price Target: $15
Current: $8.78
Upside: +70.84%
May 31, 2024
Initiates: Overweight
Price Target: $10
Current: $0.58
Upside: +1,620.87%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $3.13
Upside: +2,136.42%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $1.48
Upside: +3,345.95%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $4.76
Upside: +404.20%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $2.01
Upside: +1,591.54%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $6.43
Upside: +7,676.05%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $7.80
Upside: +79.49%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $743.35
Upside: -7.04%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $0.87
Upside: +1,049.29%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $0.30
Upside: -
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $20.31
Upside: +397.29%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $123.29
Upside: -44.03%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $451.23
Upside: -65.65%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $2.12
Upside: +6,315.09%